Recent Updates
Recently added Catalysts

APS

Phase 1

Osteoarthritis, Knee | Monoclonal antibody | Musculoskeletal |Zimmer Biomet Holdings, Inc.|Last Updated: Feb 14, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment11
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02262364Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)PHASE1 COMPLETED 11Nov 1, 2014Oct 1, 2016Feb 14, 2019 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
APSBIOLOGICALSee above
Unlock Study Design Details